Myriad Genetics, Inc. - Form 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., covering the period ended March 31, 2001. The company operates in the fields of proteomics and gene-based medicine, focusing on therapeutic product development and predictive medicine testing. As of May 11, 2001, the company had 23,265,453 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2001 | Nine Months Ended Mar 31, 2001 |
|---|---|---|
| Total Revenues | $11,567,239 | $34,340,414 |
| Net Loss | ($1,728,044) | ($4,987,952) |
| Loss Per Share (Basic & Diluted) | ($0.07) | ($0.22) |
| Cash and Cash Equivalents | $96,201,023 (Balance Sheet) | $96,201,023 (Balance Sheet) |
| Net Cash Used in Operating Activities | N/A | ($7,612,197) |
| Net Cash Provided by Financing Activities | N/A | $66,163,825 |
| Accumulated Deficit | ($57,649,934) | ($57,649,934) |
Revenue Breakdown (Nine Months 2001): Research revenue was $22,409,558; Predictive medicine revenue was $11,930,856.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% for the nine months ended March 31, 2001, compared to the prior year. Predictive medicine revenue grew 97% year-over-year due to increased testing volume and wider medical acceptance.
- Expense Increases: Research and development expenses rose 31% to $26.6 million, driven by internal drug discovery efforts. Selling, general, and administrative expenses increased 26% to $12.3 million, largely due to marketing costs for predictive medicine products.
- Liquidity Position: Cash, cash equivalents, and marketable investment securities increased by approximately $80.3 million (133%) compared to March 31, 2000. This was primarily due to a private sale of common stock raising approximately $87 million and advance payments from collaborators.
- Operating Cash Flow: The company shifted from generating $12.0 million in operating cash flow in the prior nine-month period to using $7.6 million in the current period, largely due to a decrease in deferred revenue.
Outlook, Risks, and Unusual Items
- New Alliance: In April 2001, the company announced a new alliance with Hitachi, Ltd., Friedli Corporate Finance A.G., and Oracle Corp. to form Myriad Proteomics, Inc. Myriad contributed technology valued at $82 million for a 50% ownership interest.
- Acquisition: In December 2000, the company acquired exclusive rights to MPC-7869, a drug candidate for prostate and colon cancer, from Encore Pharmaceuticals, Inc., involving a $2.7 million equity investment.
- Profitability Outlook: Management expects to incur losses for at least the next several years due to the expansion of R&D, drug discovery, and predictive medicine marketing. Future capital requirements are expected to be substantial.
- Risks: Key risks include intense competition, uncertainties regarding regulatory approval for therapeutics, the ability to commercialize predictive medicine products, and potential lack of reimbursement from third-party payors.
- Unusual Items: Income taxes of $500,000 represent withholdings by the Japanese government on collaboration payments from Hitachi. A loss on disposition of assets of $283,113 occurred due to retiring unproductive assets.
Investor Verification Checklist
- Verify the sustainability of the 97% growth rate in predictive medicine revenue and the associated customer acquisition costs.
- Confirm the terms and potential milestone payments of the new Myriad Proteomics alliance and the MPC-7869 drug acquisition.
- Assess the timeline for regulatory approval of drug candidates and the associated capital burn rate.
- Review the company's ability to secure future funding given the expectation of continued losses and substantial capital requirements.
- Monitor the impact of the $500,000 tax withholding on future collaboration payments from Hitachi.